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CholesterolThe replicative cycle of the human immunodeﬁciency virus type-1 begins after fusion of the viral and target-cell
membranes. The envelope glycoprotein gp41 transmembrane subunit contains conserved hydrophobic domains
that engage and perturb the merging lipid bilayers. In this work, we have characterized the fusion-committed
state generated in vesicles by CpreTM, a synthetic peptide derived from the sequence connecting the
membrane-proximal external region (MPER) and the transmembrane domain (TMD) of gp41. Pre-loading
cholesterol-rich vesicles with CpreTM rendered them competent for subsequent lipid-mixing with
ﬂuorescently-labeled target vesicles. Highlighting the physiological relevance of the lasting fusion-competent
state, the broadly neutralizing antibody 4E10 bound to the CpreTM-primed vesicles and inhibited lipid-mixing.
Heterotypic fusion assays disclosed dependence on the lipid composition of the vesicles that acted either as
virus or cell membrane surrogates. Lipid-mixing exhibited above all a critical dependence on the cholesterol
content in those experiments. We infer that the fusion-competent state described herein resembles bona-ﬁde
perturbations generated by the pre-hairpin MPER–TMD connection within the viral membrane.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Fusion of the surrounding envelope with the target cell membrane
precedes the entry of the human immunodeﬁciency virus type-1
(HIV-1) into the host cell. The fusion reaction is mediated by the enve-
lope glycoprotein (Env) transmembrane gp41 subunit (reviewed in
[1–3]). Two distinct types of structural elements within the gp41
ectodomain are involved in the promotion of the process: the six-helix
bundle (6-HB) or trimeric “hairpin”, a helical domain that closes by
zippering, and two membrane-transferring hydrophobic regions, the
N-terminal fusion peptide (FP) and the C-terminal membrane-
proximal external region (MPER), the latter located preceding the trans-
membrane domain (TMD) (Fig. 1A).
The prevailing mechanistic model posits that upon fusion activation
FP andMPER–TMD regions anchor the target cell and viral membranes,
respectively. Subsequent formation of the 6-HB involves the packing of
C-terminal (CHR) and N-terminal (NHR) helical regions in reverse
direction [4,5]. As a consequence, the anti-parallel helices place the FP
and MPER–TMD regions at the same end of the 6-HB. Thus, it is
assumed that the conformational energy released upon 6-HB formation
can be coupled to pull membranes together. Although not so detailedPV/EHU) and Departamento de
asco, Aptdo. 644, 48080 Bilbao,
iz), joseluis.nieva@ehu.esstructural information exists, some of the “pre-hairpin” intermediate
stages can be identiﬁed by functional experiments combining inhibitory
peptides and lipids with temperature jumps [2]. These transient and
reversible protein structures assist formation and stabilization of lipid
intermediates evolving along the fusion pathway, i.e., apposed curved
bilayers, hemifused bilayers andﬂickering fusion pores [2,3]. In contrast,
6-HB completion would be coupled to the formation of an irreversible
fusion pore, the proteolipid structure mediating the release of the
luminal content of the virus into the cytoplasmic matrix [6].
With regards to the entry process, it has been argued that HIV-1
productive infection predominantly occurs upon endocytosis of the
viral particles and fusionwith endosomes [7,8]. According to this mech-
anism, fusion activation and initial exchange of lipids occur at the
plasmamembranemediated by ‘fusogenic pre-bundles’, while eventual
release of the capsid through the fusion pore depends on endosome-
resident factors [8,9]. Thus, initiation of fusion at the plasmamembrane
would not require the folding into the ﬁnal 6-HB structure, implying
that prior to their mechanical coupling, the bilayers must undergo
focal perturbations to exchange their lipids [10].
Accumulating evidence indicates that insertion of MPER would be
required to generate hydrophobic discontinuities within the rigid viral
membrane [11–16]. MPER is highly enriched in conserved aromatic
residues that promote partitioning from water into the membrane
interface (reviewed in [17]). Mutational analyses provided early evi-
dence supporting the involvement of this domain in HIV-1 fusion [11,
18], most likely by disrupting envelope lipid packing [19] and/or by
establishing favorable interactions with the Chol-rich viral membrane
Fig. 1. Fusion-committed state generated in vesicles by CpreTM. A) Designation of the HIV-1 gp41MPER–TMD connecting sequence. The schematic diagram designates gp41 regions: FP,
fusion peptide; HR1 and HR2, amino- and carboxy-terminal helical regions, respectively; MPER, membrane-proximal external region; TMD transmembrane domain. The CpreTM peptide
sequence covers Env residues 671–693 (below). B) Left: kinetics of CpreTM incorporation into vesicles monitored bymeasuring energy transfer from tryptophans to membrane-residing
d-DHPE. The peptide was added to a vesicle suspension (100 μM lipid) at the time indicated by the arrow (t= 50 s). The peptide-to-lipid ratiowas 1:150 in this assay. Right: Lipid-mixing
assay based on the use of fusion-committed vesicles. Unlabeled POPC:Chol (1:1) vesicles (90 μM lipid)were primed at t = 60 swith CpreTM under conditions allowing fast incorporation
of the peptide (indicated by the 1st intensity spark). Further co-incubationwith the ﬂuorescently-labeled target vesicles devoid of peptide (10 μM lipid) resulted in themixing of the con-
stituent lipids of both types of vesicles, monitored as the dilution of the probes into the whole vesicle population (arrow at t = 180 s). The ﬁnal CpreTM-to-lipid ratio was 1:300. Control
blank vesicles without CpreTM underwent no lipid-mixing upon target vesicle addition (−CpreTM trace). The dotted trace follows lipid-mixing of CpreTM-primed vesicles that were
treated with MAb4E10 (10 μg mL−1) prior to target vesicle addition (2nd intensity spark at t = 120 s). Lipid-mixing was strongly attenuated in this case.
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(CRAC) LWYIK sequence located at its C-terminus [20–22] (Fig. 1A).
MPER function in viral entry is further supported by recent ﬁndings
indicating that anti-MPER neutralizing antibodies, such as 4E10, have
evolved mechanisms to recognize membrane-inserted epitopes and
block their membrane activity [23–27].
To get further insight into the fusion-related properties of the MPER
domain, we have characterized in recent work the interaction of the
CpreTM peptide with Chol-containing membranes [16,28,29]. The
CpreTM sequence includes N-terminal TMD residues that may contrib-
ute to MPER interactions with the viral membrane components, partic-
ularly with Chol [16,30] (Fig.1A). In addition, it was C-terminally
truncated at a hydrophobicity minimum, which was shown later to
encompass a putative metastable kink at the TMD [28,31]. We have
recently reported all-atom Molecular Dynamics Simulations (MDS)
revealing the activity of CpreTM in Chol-rich membranes [32]. Those
studies conﬁrmed partitioning of the sequence into the membrane
interface and establishment of phospholipid–aromatic interactions
therein. These interactions resulted in head-group condensation and
concomitant disorder of acyl chains, which in turn led to phospholipid
protrusion and acyl-chain splay. Moreover, lipid vesicles treated with
CpreTM acquired the capacity to fuse with a supplement of untreated
vesicles.
Here we sought to characterize the fusion commitment state gener-
ated by CpreTM in Chol-richmembranes. The broadly neutralizing 4E10
antibody reverted the fusion-competent state by targeting CpreTM
dimers. Moreover, in heterotypic vesicle fusion assays we found that
transmission of the CpreTM-generated perturbation from the fusion-
committed into the target membranes depended primarily on the
Chol content. Notwithstanding the Chol effect, the presence of
sphingomyelin (SM) signiﬁcantly enhanced the susceptibility of target
membranes to undergo fusion with vesicles primed by low CpreTM
doses. Collectively, our ﬁndings support an adaptation of MPER–TMD
connecting sequence for perturbing the highly rigid, Chol-rich HIV
envelope during the ﬁrst stages of the fusion process.2. Materials and methods
2.1. Materials
The peptide sequences derived from the gp41 MPER–TMD region,
KKK-NWFDITNWLWYIKLFIMIVGGLV-KK (CpreTM), and KKK-
NAADITNWLWYIKLFIMIVGGLV-KK (Cala), were produced by solid-
phase synthesis using Fmoc chemistry as C-terminal carboxamides
and puriﬁed by HPLC. To increase water-solubility both peptides
incorporated 5 additional Lys residues (in italics) [33]. 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE), egg sphingomyelin (SM) and
cholesterol (Chol) were purchased from Avanti Polar Lipids (Birming-
ham, AL, USA). The N-(5-dimethylaminonaphtalene-1-sulfonyl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (d-DHPE), N-(7-
nitro-benz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine (N-NBD-
PE) andN-(lissamine Rhodamine B sulfonyl)phosphatidylethanolamine
(N-Rh-PE) ﬂuorescent probeswere fromMolecular Probes (Eugene, OR,
USA). Rabbit anti-human IgG-HRP was obtained from Santa Cruz
Biotechnology (Dallas, Texas, USA). Monoclonal 4E10 antibody
(MAb4E10) was kindly donated by D. Katinger (Polynum Inc., Vienna,
Austria).2.2. Lipid vesicle preparation
Large unilamellar vesicles (LUV) were prepared according to the
extrusion method in 5 mM Hepes, 100 mM NaCl (pH 7.4) using
membranes with a nominal pore-size of 0.1 μm. Distributions of vesicle
sizes were determined by quasielastic light scattering using a Malvern
Zeta-Sizer Nano ZS instrument (Malvern Instruments, Malvern, UK).
The mean diameter of POPC:Chol 1:1 (mol:mol) vesicles was 118 nm.
After extrusion, phospholipid and Chol concentrations of liposome
suspensions were respectively determined by phosphate analysis and
the cholesterol oxidase/peroxidase method (BioSystems, Barcelona,
Fig. 2. CpreTM peptide binding to vesicles. A) Partitioning of CpreTM peptide into POPC:
Chol (1:1) vesicles. Left: intrinsic ﬂuorescence emission spectra (excitation wavelength:
280 nm) of the peptide incubated with increasing concentrations of vesicular lipid. Pep-
tide concentration was 0.5 μM. Lipid concentrations were (from bottom to top): 0, 5, 10,
20, 40, 60 and 100 μM. Right: Changes in maximum emission wavelength (top) and frac-
tional intensity (bottom) upon incubation with vesicles. B) Top: vesicle ﬂotation experi-
ments in sucrose gradients. CpreTM (15 μM) was added to POPC:Chol (1:1) vesicles at a
peptide-to-lipid ratio of 1:100. The presence of the peptide in the different fractions was
probed with MAb4E10 in Western blot. Virtually all input peptide co-ﬂoated with lipo-
somes indicating quantitative partitioning into membranes. Rhodamine emission
(below) denoted the presence of vesicles in the fractions. Bottom: the peptide incubation
was made in the absence of vesicles. In this case CpreTM was mainly recovered from the
SDS fraction after centrifugation.
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found to be 48.6 ± 2.6 (mean ± S.D., n = 12).
2.3. Membrane binding assays
Corrected Trp spectra were recorded using a FluoroMax-3 (Jobin
Ybon, Horiba) with excitation set at 280 nm and 2-nm slits. Degree of
peptide association with the vesicles was estimated from the shifts in
the maximum emission wavelength and the fractional changes in
emitted ﬂuorescence. Kinetics of partitioning was measured by energy
transfer from the Trp peptide to the surface d-DHPE ﬂuorescent probe
as in [15]. In brief, 6 mol% of the d-DHPE probe was included in the
target vesicle composition and its ﬂuorescence was measured at an
emission wavelength of 510 nm, while the excitation wavelength was
that of the Trp residue (280 nm).
Vesicle ﬂotation in sucrose gradients was performed following the
method described by Yethon et al. [34]. 100 μl of a sample containing
N-Rh-PE-labeled liposomes (1.5 mM lipid concentration) was adjusted
to a sucrose concentration of 1.4 M in a ﬁnal volume of 300 μl, and
subsequently overlaid with 400 and 300 μl-layers of 0.8 and 0.5 M
sucrose, respectively. The gradient was centrifuged at 436,000 ×g for
3 h in a TLA 120.2 rotor (Beckman Coulter, Brea, CA, USA). After centri-
fugation, four 250 μl-fractions were collected. Material adhered to the
tubes was collected into a 5th fraction by washing with 250 μl of hot
(100 °C) 1% (w/v) SDS. The presence of CpreTM and/or Mab4E10 in
the different fractions was revealed by Western blot analysis after
SDS-PAGE separation.
2.4. Lipid-mixing with fusion-committed vesicles
Membrane lipid mixing was monitored using the resonance energy
transfer (RET) assay, described by Struck et al. [35]. The assay is based
on the dilution of N-NBD-PE and N-Rh-PE. Dilution due to membrane
mixing results in an increased N-NBD-PE ﬂuorescence. Vesicles contain-
ing 0.6 mol% of each probe (target vesicles) were added at 1:10 ratio to
unlabeled vesicles (routinely CpreTM-primed vesicles). The ﬁnal lipid
concentration in the mixture was 100 μM. The ensuing increase in
NBD emission upon mixing of target-labeled and primed-unlabeled
lipid bilayers was monitored at 530 nmwith the excitation wavelength
set at 465 nm. A cutoff ﬁlter at 515 nm was used between the sample
and the emission monochromator to avoid scattering interferences.
The ﬂuorescence scale was calibrated such that the zero level
corresponded to the initial residual ﬂuorescence of the labeled vesicles
and the 100% value to complete mixing of all the lipids in the system
(i.e., the ﬂuorescence intensity of vesicles containing 0.06 mol% of
each probe).
3. Results
3.1. Fusion-competent state generated in vesicles by CpreTM
Our recentwork supports the involvement of theMPER–TMD region
spanning Env residues 671–693 (Fig. 1A) in the focal disruption of the
Chol-enriched viral membrane [16,32]. Particularly, MDS revealed that
CpreTM, a peptide based on the MPER–TMD linker, inserted subtly
into the membrane–interface and induced therein phospholipid and
acyl-chain extraction, a lasting perturbation that could prime Chol-
rich membranes for fusion [32]. The goal of the present study is to get
further insights into the fusion-committed state generated by CpreTM,
and on the lipid requirements that govern its propagation into target
membranes.
Results shown in Fig. 1B evidence lipid exchange between CpreTM-
primed vesicles and ﬂuorescently-labeled target vesicles devoid of
peptide. The kinetics of energy transfer from Trp residues to the dansyl
moieties at the membrane interface demonstrated that CpreTM
partitioned from water into membranes in less than 10 s (left panel).The right panel discloses the time course of the assay using the fusion-
committed vesicles. At time 60 s (indicated by the ﬂuorescence intensi-
ty spark labeled as “+CpreTM”), peptide (0.33 μM) was added to the
unlabeled-vesicle solution (90 μM lipid), and, after 120 s (indicated by
the arrow), the mixture was supplemented with N-NBD-PE/N-Rh-PE-
labeled vesicles (10 μM lipid). The resulting increase in NBD ﬂuores-
cence over time was consistent with the dilution of the probes upon
mixing of lipids of target and primed vesicles (+CpreTM trace). Such
increase was strongly attenuated upon addition of the MAb4E10
antibody prior to the target vesicles (+4E10, dotted trace), and not ob-
served at all upon incubation of vesicles following the same protocol but
in the absence of peptide (−CpreTM trace). Together, these results sup-
port that perturbations speciﬁcally induced by CpreTM on one vesicle
population could be transmitted into target vesicles devoid of peptide,
a phenomenon that resulted in the mixing of their constituent lipids.
However, the fusion phenomenon described in the previous ﬁgure
could be elicited by a fraction of unbound peptide, and/or evolve as a
consequence of peptide-induced vesicle solubilization. Thus, experi-
ments were conducted to ensure that CpreTM bound quantitatively
and irreversibly under the conditions selected to prime membranes
Fig. 3. Size distribution of the vesicles determined by light scattering. POPC:Chol (1:1)
vesicles were measured before (LUV, circles) and after 15 min incubation with CpreTM
(peptide-to-lipid ratio of 1:100) (+CpreTM, squares). Vesicles treated with Triton X-
100 (10% v/v) are shown as a reference for the size of micelles (micelles, triangles).
1017B. Apellániz, J.L. Nieva / Biochimica et Biophysica Acta 1848 (2015) 1014–1022(Fig. 2), and that its activity did not cause vesicle disintegration follow-
ing a detergent-like mechanism (Fig. 3). Changes in CpreTM Trp emis-
sion intensity indicated that partitioning into POPC:Chol (1:1) vesicles
reached saturation with ca. 50 μM lipid (Fig. 2A). Therefore, peptide
binding was considered quantitative at the lipid concentration used to
generate fusion-committed vesicles (90 μM lipid). The shift of themax-
imum emission wavelength was subtle at those concentrations (ca.
5 nm), consistent with a peptide interaction restricted to the most
polar, peripheral region of the bilayer. Even though, the peptide interac-
tion with vesicles was tight as put forward by ﬂotation experiments,
which disclosed the added peptide co-ﬂoatingwith vesicles upon phys-
ical separation of bound and unbound species by ultracentrifugation
(Fig. 2B-top). In these experiments the peptide incubated in the absence
of vesicles was recovered from the pellets, mostly in the SDS fraction
(Fig. 2B-bottom). Thus, the fact that upon incubation with vesicles un-
bound peptide was not detected in solution, supports the irreversible
CpreTM insertion into lipid bilayers. Finally, results displayed in Fig. 3
conﬁrmed that perturbations induced by CpreTM did not causeFig. 4. 4E10 antibody association to fusion-committed vesicles in ﬂotation experiments. A) MA
vesicles before centrifugation. Consistent with antibody binding to CpreTM-primed vesicles, MA
pellets when vesicles were loaded with Cala peptide. C) MAb4E10 incubated with POPC:Chol (1
incubated in the absence of vesicleswas not present inﬂoating fractions. Thepresence of the antib
emission denoted the presence of the vesicles in the fractions (spectra displayed in the panels cmembrane micellization, but rather a discrete increase of the vesicle
mean diameter from ca. 120 to ca. 550 nm.
3.2. Association of MAb4E10 to fusion-committed vesicles
Results shown in the previous ﬁgures suggest that CpreTMwas capa-
ble of inducing a lasting fusion commitment state in POPC:Chol (1:1)
vesicles, which otherwise maintained their integrity. Data displayed in
Figs. 4 and 5 further demonstrate that the HIV neutralizing MAb4E10
could associate to these vesicles and reverse the fusion-competent state.
In liposome-based ﬂotation experiments, the whole input antibody co-
ﬂoated with CpreTM-primed vesicles (Fig. 4A). In contrast, the antibody
did not co-ﬂoat with the vesicles loaded with the Cala peptide, which
bears the 4E10 key epitope residues Trp-Phe, critical for binding, mutated
to Ala-Ala (Fig. 4B). This peptide otherwise partitions into POPC:Chol ves-
icles almost as efﬁciently as CpreTM (partitioning constants, Kx, of 3 × 106
and 5 × 106, respectively), and induces lipid-mixing [32]. In the Cala
sample the presence of a faint protein band in the ﬂoating fractions
evidenced the existence of some residual antibody–membrane binding.
Similarly, the bulk ofmembrane bindingwas absent in the vesicles devoid
of peptide (Fig. 4C). Floating antibodywas not detected eitherwhen incu-
bated in solution in the absence of vesicles (Fig. 4D). These observations
underpin MAb4E10 binding to CpreTM-primed vesicles, and the depen-
dence of the process on speciﬁc epitope recognition.
As shown by the dotted trace in the previous Fig. 1B-right, antibody-
treated vesicles underwent ameliorated lipid-mixing. Antibody
titrations shown in Fig. 5 further indicate that 4E10 inhibited the lipid-
mixing process in a dose and epitope recognition-dependent way.
Moreover the inhibition curve saturated at approximately the 0.5
value (paratope:peptide mole ratio) consistent with an apparent 1:2
stoichiometry for the paratope–peptide association reaction.
3.3. Heterotypic vesicle fusion dependence on the Chol content of membranes
The lipid-mixing assay based on the use of fusion-committed
vesicles allowed performing heterotypic vesicle fusion assays. Given
the relevance of Chol for the HIV fusion process [36,37] (see alsob4E10 (45 μg mL−1) was incubated for 15 min with CpreTM-containing POPC:Chol (1:1)
b4E10 was recovered from the ﬂoating fractions. B) MAb4E10 was mainly recovered from
:1) vesicles in the absence of CpreTM was also detected mainly in the pellets. D) Antibody
ody in thedifferent fractionswas probedwith anti-human IgG byWestern blot. Rhodamine
orresponding to vesicle-containing samples).
Fig. 5. Lipid-mixing inhibition by 4E10 antibody. CpreTM-primed vesicles were incubated
with increasing amounts ofMAb4E10 prior to the addition of target vesicles (circles). Cala-
primed vesicles were used as negative control to probe the speciﬁcity of the process
(squares). The dotted line begins at the paratope-to-peptide ratio of 0.5:1. Plotted values
are means ± SD of three experiments.
Fig. 6. Lipid-mixing dependence on theChol content of vesicles. A) Kinetics of lipid-mixingwere
as indicted on top of the panels. Unlabeled vesicles were primed by adding CpreTM at the pept
labeled target-vesicles. The ﬁnal lipid concentration was 100 μM. B) Top panels: Final extents o
Chol (1:1); (■), POPC:Chol (2:1); (▲), POPC:Chol (4:1); (▼), POPC. The percentage of lipid-mi
tration used to prime unlabeled vesicles. Bottom panels: Levels of lipid-mixing measured after
CpreTM at a ﬁnal peptide-to-lipid mole ratio of 1:100 in this case. Means ± SD values of three
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component of either primed or target vesicles (Fig. 6). The kinetic traces
displayed in Fig. 6A illustrate the effect of reducing Chol from 50 mol%
(POPC:Chol (1:1)) to 33 mol% (POPC:Chol (2:1)) in either CpreTM-
primed or target vesicles. Priming POPC:Chol (1:1) vesicles with CpreTM
at peptide-to-lipid ratios ranging between 1:1000 and 1:100 resulted in
efﬁcient and dose-dependent lipid-mixing with target vesicles of the
same composition (left panel). Reduction of the Chol content in the
CpreTM-primed vesicles severely interfered with the process (center
panel). In contrast, the same Chol reduction in the target vesicle compo-
sition had little effect on the measured lipid-mixing (right panel).
Plots of the extents of lipid-mixing after 10 min vs. CpreTM concen-
tration disclosed more clearly the differential effects of Chol on either
CpreTM-primed or target vesicles (Fig. 6B, left and right panels, respec-
tively). Effective promotion of lipid-mixing was above all observed for
the primed 1:1 vesicles and for all target vesicles that contained Chol
(top panels). The titration curves exhibited a sigmoidal shape consistent
with the involvement of cooperative effects in peptide-induced fusionmeasured for different combinations of POPC:Cholmole ratios in Primed or Target vesicles,
ide-to-lipid ratios indicated in the traces. The t = 0 s corresponded to the addition time of
f lipid mixing for different compositions in Primed or Target vesicles. Symbols: (●), POPC:
xing measured after a 10 min incubation was plotted as a function of the CpreTM concen-
10min were plotted vs. the Chol mole fraction. Unlabeled vesicles were primed by adding
experiments are shown.
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the Chol mole fraction further revealed a sharp enhancement of primed
vesicle fusion at the highest Chol concentration (bottom-left). In
contrast, the target vesicles showed amore gradual increasewith values
close to its maximum already attained with 33 mol% of Chol (bottom-
right). In conclusion, in the heterotypic vesicle fusion assay, CpreTM-
induced lipid mixing showed more stringent dependency on the Chol
content of primed membranes as compared to target ones.
3.4. Effect of target membrane lipid composition
The heterotypic vesicle fusion approach was ﬁnally applied to study
the effect of other relevant lipids as components of the target
membranes (Figs. 7 and 8). Phospholipids with larger cross-sectional
area available for the acyl chain tails and a small area available for the
headgroups, such as phosphatidylethanolamine, impart mean negative
curvature on membrane monolayers and sustain membrane fusion
phenomena by promoting the formation of non-lamellar lipid struc-
tures [38]. On the other hand, the outer layer of the plasma membrane
is enriched in sphingolipids and sterols, which are tightly packed and
resist mechanical stress [39,40]. Thus, phosphatidylethanolamine in
one hand, and sphingomyelin/Chol on the other, are predicted to
contribute in disparate ways to lipid-mixing: the former by eliciting
the process, the latter by interfering with it. To compare lipids of each
kind, half of the POPC in the POPC:Chol (2:1) mixture was substituted
by either POPE or SM to render POPC:POPE:Chol (1:1:1) or POPC:SM:
Chol (1:1:1) target vesicles, respectively. As shown in Fig. 7A-left, in ex-
periments using POPC:Chol (1:1) vesicles primed with CpreTM at a
1:200 peptide-to-lipid ratio, POPC:POPE:Chol (1:1:1) and POPC:SM:
Chol (1:1:1) vesicles underwent fusion following kinetics comparable
to those measured for the POPC:Chol (2:1) reference vesicles.Fig. 7. Effect of the target vesicle composition on fusion. A) Kinetics of lipid mixing. Unla-
beled POPC:Chol (1:1) vesicles were primed by adding CpreTM at the peptide-to-lipid
ratio of 1:200 (left) or 1:1000 (right). Labeled target-vesicles composed of POPC:Chol
(2:1), POPC:POPE:Chol (1:1:1) or POPC:SPM:Chol (1:1:1) were subsequently added at
t = 0 s and ensuing lipid-mixing scored over time (continuous, dotted and dashed traces,
respectively). The ﬁnal lipid concentration was 100 μM. B) Final extents and initial rates.
Percentages of lipid-mixingmeasured after 10min (left) or 10 s (right) have been plotted
as a function of the CpreTM concentration used to prime unlabeled vesicles. Symbols: (●),
POPC:Chol (2:1); (■), POPC:POPE:Chol (1:1:1); (○), POPC:SM:Chol (1:1:1). Means ± SD
values of three experiments are shown.Interestingly however, upon lowering the CpreTM dose to 1:1000
peptide-to-lipid ratio, substantial lipid-mixingwas only and consistent-
ly observed in the case of POPC:SM:Chol (1:1:1) target vesicles (Fig. 7A-
right). Calculations of ﬁnal extents and initial rates put forward that, be-
sides the signiﬁcant SM effect observed with low CpreTM concentra-
tions, vesicles containing POPE or SM, while slightly more susceptible
to fusion, did not differ substantially in fusogenicity from the reference
vesicle population (Fig. 7B). These observations suggest that propaga-
tion of the CpreTM-induced perturbation into the target membrane fol-
lows a mechanism that is not dependent on its propensity to form non-
lamellar structures. Moreover, vesicles reﬂecting the stability of the
plasma membrane outer leaﬂet were also competent in exchanging
lipids with the fusion-committed vesicles.
The results displayed in Fig. 8 illustrate the effect of approximating
the plasmamembrane external leaﬂet composition on the susceptibility
of targetmembranes to undergo fusionwith blank vesicles, whichwere
primedwith low CpreTM doses (i.e., 1:500 peptide-to-lipid mole ratio).
Inclusion of Chol and then SM increased the rate and extent of the lipid
mixing (Fig. 8A). Of note, even if included at low doses, the lipid
exchange was in all cases dependent on the presence of CpreTM.
Moreover, data shown in Fig. 8B conﬁrm that the extent of the fusion
process measured under those conditions was signiﬁcantly higher
upon inclusion of SM. These results suggest that target vesicles includ-
ing lipids that are predominantly located at the external side of the
plasma membrane, not only were competent to undergo fusion, but
also seemed to reﬂect an optimal condition for the process to evolve.
4. Discussion
Analyses of the HIV envelope lipidome are consistent with viral
assembly taking place within Chol-rich domains of the host-cell plasma
membrane [41,42]. Thus, to initiate a new replicative cycle the rigid
envelope must be forced to merge with the less ordered target-cell
membrane (see [14] for a discussion). Our recent ﬁndings indicate
that the fusogenic activity of CpreTM, a peptide representing the
MPER–TMD connection, is elicited at the Chol concentrations existing
at the viral envelope [32]. MDS studies further revealed the capacity of
this sequence to perturb the membrane interface, by promoting
exposure of acyl-chains to solvent, or even by extracting complete
phospholipid molecules under those conditions [32]. The observation
of CpreTM-induced fusion would be in accordance with the ﬁnding
that peptides containing the LWYIK CRAC motif lowered the bending
modulus (kc) in Chol-containing membranes [43]. A similar reduction
of the kc parameter was described for the inclusion in model
membranes of the N-terminal FP [44,45]. Thus, reduction of kc supports
that both sequences, FP and CpreTM,might in a concertedmanner assist
bending of the membranes into highly curved fusion intermediates
during viral fusion.
Here, we describe two characteristics of CpreTM-induced perturba-
tion that underline its biological relevance. On the one hand, a neutral-
izing antibody could associate to the fusion-committed vesicles and
revert their state (Figs. 4 and 5). On the other, prominently at low
CpreTM doses, requirements of the target vesicle composition reﬂected
conditions of the plasma membrane leaﬂet that ﬁrst exchanges lipids
with the viral envelope (Figs. 6–8). We surmise that the lipid-mixing
of fusion-committed vesicles described in this work (Fig. 1) might
comprise a bona-ﬁde reﬂection of MPER–TMD region activity within
pre-hairpin structures [2,3].
Even though perturbations triggered by CpreTM may result in
phospholipid extraction [32], the experimental results displayed in
Figs. 2 and 3 demonstrate that the peptide remains associated to
vesicles and that its interaction does not cause their micellization.
Indeed, incubation with CpreTM led to the formation of bigger vesicles
with sizes ranging between 300 and 700 nm. Thus, our data are consis-
tent with the generation of a fusion-competent state that lasts at the
surface of the larger vesicles, and with the subsequent transmission of
Fig. 8. Effects of Chol and SM on target membrane susceptibility to undergo fusion at low CpreTM doses. A) Kinetics of lipid mixing. Unlabeled POPC:Chol (1:1) vesicles were primed by
adding CpreTM at the peptide-to-lipid ratio of 1:500. Conditions otherwise as in the previous ﬁgure. Dashed traces correspond to controls without CpreTM. B) Signiﬁcant enhancement of
lipid-mixing levels upon inclusion of SM. Lipid-mixing extents were measured after 10min incubation of target and primed-blank vesicles. The latter were pre-incubated with CpreTM at
1:500 or 1:1000 peptide-to-lipid ratios. The t-probability values were *p b 0.05 for unpaired set of data.
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peptide. Importantly, the CpreTMpeptide primed the vesicles for fusion
atmembrane doses ranging between 1:1000 and 1:100 peptide-to-lipid
mole ratios (Fig. 6A). These doses are ca. 1 order of magnitude lower
than those commonly used to assay synthetic peptides as fusogens
[46], which further underlines the speciﬁcity of the measured process.
Evidencing the biological relevance of this phenomenon, the 4E10
antibody bound to fusion-committed vesicles and blocked the lasting fu-
sion state (Figs. 4 and 5). This antibody targets the subset of pre-hairpin
intermediates to block fusion [47]. Interestingly, the dose–inhibition
curve suggests that MAb4E10 blocks fusion by targeting CpreTM dimers
(Fig. 5). Consistentwith thepossibility that CpreTMdimers represent the
membrane-active form of the peptide, SDS-resistant dimers were the
predominant species observed after gel-electrophoresis [28], and MDS
disclosed dimers as the active forms inducing acyl-chain splay and
phospholipid protrusion [32]. Recently solved crystals of trimeric, pre-
fusion Env display the C-termini of the CHR domains hanging free from
each protomer, consistent with the absence of inter-protomer interac-
tions at the level of the MPER D664 residue [48]. Thus, although MPER
constitutes a part of the trimeric gp41 in the native glycoprotein, its
sequence is predicted to insert into the viral membrane in monomeric
form. We speculate that MPER–TMD dimerization might occur upon
fusion activation, possibly when 4E10 binding is boosted [47,49].
In addition, the ﬂotation assays displayed a small fraction of anti-
body bound tomembranes devoid of peptide (Fig. 5A). A similar ﬁnding
has been recently reported and discussed as indicative of MAb4E10
capacity for directly interacting with the viral membrane [49]. Since
the 4E10 epitope would be only fully accessible upon fusion activation,
it has been argued that pre-concentrating the antibody at the viral
membrane surface is a required step for the neutralization mechanism
to evolve [49]. Alternatively, cross-reactivity with lipids has led to the
proposal that the 4E10 epitope may comprise a proteo-lipid complex
[15,25,27]. The observations that generation of the fusion-committedstate may involve exposure of phospholipid moieties by CpreTM [32],
and that the reversion of this condition may be attained by incubation
with antibody (Fig. 5) would support this latter idea.
The fusion-competent vesicles were further used to assess hetero-
typic vesicle fusion (Figs. 6–8). This approach allowed getting insights
into the Chol requirements in either primed or target vesicles (Fig. 6).
Our experiments revealed that a Chol concentration comparable to
that existingwithin virions [41,42], was required in the vesicles to effec-
tively generate the fusion-committed state. In contrast to the critical
dependence observed for the primed vesicles, lipid-mixing increased
gradually upon increasing the Chol content of the target vesicles. Thus,
target vesicles containing Chol concentrations in the range found in
the plasma membrane of virus-producing cells (ca. 30 mol% [41,42]),
efﬁciently mixed their lipids with the fusion-committed vesicles. The
fact that MPER-derived sequences are dependent on Chol for fusing
vesicles was noted in an earlier study [14]. Our results add to this notion
that the critical Chol-dependency speciﬁcally pertains to the vesicles
acting as surrogates of the viral membrane. Interestingly, HIV
membrane-like complex lipid mixtures that contain 45 mol% Chol,
display low kc values allowing highly curved intermediates to form
[50]. This suggests that the viral membrane composition and the
CpreTM sequence might have co-evolved to sustain efﬁcient fusion.
The heterotypic fusion measurements allowed further analysis of
the target-membrane composition requirements (Figs. 7 and 8). In the
plasmamembrane PE is predominantly exposed on the cytosolic leaﬂet,
whereas PC and SM are predominantly located on the outer leaﬂet [39,
40]. Thus, the cell membrane (cis-)monolayer that makes ﬁrst contact
with the viral envelope is presumptively devoid of non-lamellar lipids.
On the contrary, this monolayer is expected to be enriched in lipids
conferring high packing density and, hence, resistance to bending.
Thus, the observations that PE did not appreciably stimulate lipid-
mixing, or that the inclusion of SM did not interfere with the process
(Fig. 7), would not be at odds with the putative requirements for the
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ed cell [2,9]. Moreover, at low CpreTM doses (i.e. 1:1000 or 1:500
peptide-to-lipid ratio) a signiﬁcant enhancement of lipid mixing was
observed upon inclusion of SM into the target membrane (Fig. 8). We
note that the low CpreTM dose condition might be relevant for the
HIV fusion process, since the low number spikes existing at the
envelope (10–20 peplomers per virion [51]) implies an MPER density
close to ca. 1:5000 (MPER-to-lipid mole ratio). Thus, perturbations
generated within the viral membrane surrogate by low CpreTM doses
seem to sufﬁce for induction of lipid exchange with target membranes
resembling the outer leaﬂet of the plasma membrane.
In conclusion, our recent MDS studies and the heterotypic vesicle
fusion assays described herein have rendered relevant information for
the understanding of the initial steps of the HIV fusion reaction
triggered by fusogenic pre-hairpins. They point to the MPER–TMD
connection as a pivotal component of the HIV fusion machinery,
which would function by facilitating lipid exchange between the virus
and plasma cellmembranes. In this regard, this region should be consid-
ered as internal HIV-1 fusion peptide [52].
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